In concordance with these findings, we observed earlier that inhibition of FGFR2 signaling effectively attenuates homology-mediated DNA repair in cancer cells and sensitizes them to DNA-damaging agents (e.g., DNA topoisomerase II inhibitor doxorubicin) [159]. Here, FGFR2 is linked to cancer.